Efficacy and safety of pantoprazole in the treatment of patients with gastroesophageal reflux disease in real-world clinical practice: A multicenter observational study

Introduction. Gastroesophageal reflux disease (GERD) is a common condition leading to a considerable decrease in the quality of life of patients. Proton pump inhibitors (PPI), including pantoprazole, represent the mainstay of medical treatment of GERD. This study assessed the efficacy and safety of pantoprazole (Nolpaza®) in clinical practice.

Aim. To evaluate the clinical efficacy, safety and tolerability of pantoprazole in patients with GERD, as well as the impact of therapy on quality of life and treatment adherence.

Materials and methods. A multicenter observational study included 10,883 patients with GERD (with and without esophagitis) who received pantoprazole (40 mg/day) for 4–8 weeks. The following parameters of treatment were assessed: changes in symptoms, check-up EGD findings, frequency of adverse reactions, physician and patient satisfaction, and treatment adherence. Results. The study results allowed us to evaluate the efficacy and safety of the therapy used. Improvement was noted in more than 99% of patients (complete disappearance of symptoms in 73.4%). According to EGDS, 74.45% achieved complete remission, 25.08% partial. Adverse events (AE) were registered in 0.28% (headache, constipation, abdominal discomfort). During therapy, adherence to the drug was more than 86%, satisfaction with treatment was more than 94% among doctors and more than 95% among patients.

Conclusions. Pantoprazole demonstrated high efficacy in relieving GERD symptoms and healing mucosal lesions, a high safety profile with a minimal risk of adverse events, as well as good tolerability and high patient adherence to this therapy. Our findings favoured the use of pantoprazole as a standard therapy for GERD in real-world clinical practice.

1. Ivashkin VT, Trukhmanov AS, Maev IV, Drapkina OM, Livzan MA, Martynov AI et al. Diagnosis and Treatment of Gastroesophageal Reflux Disease (Clinical Guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Society for the Prevention of Noncommunicable Diseases, Scientific Community for Human Microbiome Research). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(5):111–135. (In Russ.) https://doi.org/10.22416/1382-4376-2024-34-5-111-135.

2. Maev IV, Andreev DN, Ovsepyan MA, Barkalova EV. Gastroesophageal reflux disease: risk factors, current possibilities of diagnosis and treatment optimisation. Meditsinskiy Sovet. 2022;16(7):16–26. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-7-16-26.

3. Маев ИВ, Бусарова ГА, Андреев ДН. Болезни пищевода. М.: ГЭОТАРМедиа; 2019. 668 с. Режим доступа: https://static-eu.insales.ru/files/1/5205/12145749/original/bol_pish.pdf.

4. Durazzo M, Lupi G, Cicerchia F, Ferro A, Barutta F, Beccuti G et al. ExtraEsophageal Presentation of Gastroesophageal Reflux Disease: 2020 Update. J Clin Med. 2020;9(8):2559. https://doi.org/10.3390/jcm9082559.

5. Jaspersen D, Kulig M, Labenz J, Leodolter A, Lind T, Meyer-Sabellek W et al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther. 2003;17(12):1515–1520. https://doi.org/10.1046/j.1365-2036.2003.01606.x.

6. Yanushevich OO, Maev IV, Krikheli NI, Andreev DN, Lyamina SV, Sokolov FS et al. Prevalence and Risk of Dental Erosion in Patients with Gastroesophageal Reflux Disease: A Meta-Analysis. Dent J. 2022;10(7):126. https://doi.org/10.3390/dj10070126.

7. Nirwan JS, Hasan SS, Babar ZU, Conway BR, Ghori MU. Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis. Sci Rep. 2020;10(1):5814. https://doi.org/10.1038/s41598-020-62795-1.

8. Andreev DN, Maev IV, Bordin DS, Abdulkhakov SR, Shaburov RI, Sokolov PhS. Prevalence of gastroesophageal reflux disease in Russia: a meta-analysis of population-based studies. Terapevticheskii Arkhiv. 2024;96(8):751–756. (In Russ.) https://doi.org/10.26442/00403660.2024.08.202807.

9. Andreev DN, Kucheryavyy YA. Obesity as a risk factor for diseases of the digestive system. Terapevticheskii Arkhiv. 2021;93(8):954–962. (In Russ.) https://doi.org/10.26442/00403660.2021.08.200983.

10. Shkolnikov VM, Churilova E, Jdanov DA, Shalnova SA, Nilssen O, Kudryavtsev A et al. Time trends in smoking in Russia in the light of recent tobacco control measures: synthesis of evidence from multiple sources. BMC Public Health. 2020;20(1):378. https://doi.org/10.1186/s12889-020-08464-4.

11. Yuan S, Larsson SC. Adiposity, diabetes, lifestyle factors and risk of gastroesophageal reflux disease: a Mendelian randomization study. Eur J Epidemiol. 2022;37(7):747–754. https://doi.org/10.1007/s10654-022-00842-z.

12. Maev IV, Andreev DN, Goncharenko AYu, Dicheva DT. Proton pump inhibitors as a basis for the treatment of acid-related diseases. Spravochnik Poliklinicheskogo Vracha. 2013;(7-8):12–14. (In Russ.) Available at: https://gastroscan.ru/literature/authors/7083.

13. Maev IV, Andreev DN, Kucheryavyy YuA, Shaburov RI. Current advances in the treatment of gastroesophageal reflux disease: a focus on esophageal protection. Terapevticheskii Arkhiv. 2019;91(8):4–11. (In Russ.) https://doi.org/10.26442/00403660.2019.08.000387.

14. Andreev DN, Kucheryavyy YuA. Prospects for the treatment of gastroesophageal reflux disease. Consilium Medicum. Gastroenterology (Suppl.). 2013;(2):9–14. (In Russ.) Available at: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2013/gastro2013_pril/gastro2013_2_pril/perspektivy-lecheniya-gastroezofagealnoy-reflyuksnoy-bolezni.

15. Maev IV, Samsonov AA, Andreev DN. Clinical significance of the syndrome of “crossing” of functional dyspepsia and gastroesophageal reflux disease. Klinicheskie Perspektivy Gastroehnterologii, Gepatologii. 2013;(5):17–22. (In Russ.) Available at: https://www.elibrary.ru/rcmjop.

16. Kucheryavy YuA, Andreyev DN. Prospects of acid-related diseases treatment. Klinicheskie Perspektivy Gastroehnterologii, Gepatologii. 2014;(2):15–24. (In Russ.) Available at: https://www.elibrary.ru/rxbwvz.

17. Welage LS. Pharmacologic properties of proton pump inhibitors. Pharmacotherapy. 2003;23(10 Pt2):74S–80S. https://doi.org/10.1592/phco.23.13.74s.31929.

18. Ward RM, Kearns GL. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs. 2013;15(2):119–131. https://doi.org/10.1007/s40272-013-0012-x.

19. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201–211. https://doi.org/10.1007/s40264-014-0144-0.

20. Dabrowski A, Štabuc B, Lazebnik L. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease – PAN-STAR. Prz Gastroenterol. 2018;13(1):6–15. https://doi.org/10.5114/pg.2018.74556.

21. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430–440. https://doi.org/10.1136/gutjnl-2016-313589.

22. Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27–56. https://doi.org/10.14309/ajg.0000000000001538.

23. Hunt R, Armstrong D, Katelaris P, Afihene M, Bane A, Bhatia S et al. World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. J Clin Gastroenterol. 2017;51(6):467–478. https://doi.org/10.1097/MCG.0000000000000854.

24. Li MJ, Li Q, Sun M, Liu LQ. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. Medicine. 2017;96(39):e8120. https://doi.org/10.1097/MD.0000000000008120.

25. Mayev IV, Zaborovsky AV, Tararina LA, Yunina DV, Andreev DN. Efficiency and Safety of Pantoprazol in Treatment of Patients with Acid Dependent Diseases in Russia: Multicenter Observe Research. Effective Pharmacotherapy. 2023;19(43):20–27. (In Russ.) https://doi.org/10.33978/2307-3586-2023-19-43-20-27.